English 
AMI Inc., which aims to realize rapid medical innovation through the research and development of AI medical devices and the social implementation of remote medical services, is pleased to announce that on December 25, 2025, it obtained pharmaceutical approval for the “Digital Biomarker DNP-AS,” a program for general-purpose phonocardiographs that it has been developing for some time.
We will continue to accelerate research and development of medical devices and related services to realize a society where anyone can receive optimal medical care anytime, anywhere.
This achievement was made possible through a project funded by the New Energy and Industrial Technology Development Organization (NEDO).
こちらもお読みください： AICX協会と医師が医療ヘルスケアAIプロジェクトを発足
AMI Inc. is an R&D startup that aims to research and develop AI medical devices and implement telemedicine in society. With the mission of “creating a society where optimal medical care is available to anyone, anywhere, anytime,” the company is working to implement the “Super Stethoscope” in society. *The “Super Stethoscope” is a collective term consisting of hardware (Cardio-EGG), software (Cloud Super Diagnosis), technology (AI and SaMD), and knowledge.
ソース PRタイムズ
日本語